KEGG   PATHWAY: npo05235
Entry
npo05235                    Pathway                                
Name
PD-L1 expression and PD-1 checkpoint pathway in cancer - Nyctereutes procyonoides (raccoon dog)
Description
Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.
Class
Human Diseases; Cancer: overview
Pathway map
npo05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
npo05235

Organism
Nyctereutes procyonoides (raccoon dog) [GN:npo]
Gene
129496195  HIF1A; hypoxia-inducible factor 1-alpha [KO:K08268]
129521218  EGF; pro-epidermal growth factor isoform X1 [KO:K04357]
129494118  EGFR; epidermal growth factor receptor isoform X1 [KO:K04361] [EC:2.7.10.1]
129494224  HRAS; GTPase HRas isoform X1 [KO:K02833]
129505561  KRAS; GTPase KRas isoform X1 [KO:K07827]
129501466  NRAS; GTPase NRas [KO:K07828]
129522592  RAF1; RAF proto-oncogene serine/threonine-protein kinase isoform X1 [KO:K04366] [EC:2.7.11.1]
129506345  MAP2K1; dual specificity mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
129522322  MAP2K2; dual specificity mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
129502349  mitogen-activated protein kinase 3-like [KO:K04371] [EC:2.7.11.24]
129507918  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
129519082  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
129496401  FOS; protein c-Fos [KO:K04379]
129497811  JUN; transcription factor Jun [KO:K04448]
129510923  EML4; echinoderm microtubule-associated protein-like 4 isoform X1 [KO:K15420]
129511167  ALK; ALK tyrosine kinase receptor [KO:K05119] [EC:2.7.10.1]
129513452  PIK3R1; phosphatidylinositol 3-kinase regulatory subunit alpha isoform X1 [KO:K02649]
129520803  PIK3R3; phosphatidylinositol 3-kinase regulatory subunit gamma isoform X1 [KO:K02649]
129522073  PIK3R2; phosphatidylinositol 3-kinase regulatory subunit beta [KO:K02649]
129496789  PIK3CD; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
129498637  PIK3CA; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922] [EC:2.7.1.153]
129507069  PIK3CB; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform [KO:K00922] [EC:2.7.1.153]
129507556  PTEN; phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
129508823  AKT3; RAC-gamma serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
129495892  AKT1; RAC-alpha serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
129499851  AKT2; RAC-beta serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
129517633  RAC-alpha serine/threonine-protein kinase-like [KO:K04456] [EC:2.7.11.1]
129514778  RAC-alpha serine/threonine-protein kinase-like [KO:K04456] [EC:2.7.11.1]
129513263  MTOR; serine/threonine-protein kinase mTOR [KO:K07203] [EC:2.7.11.1]
129501834  RPS6KB2; ribosomal protein S6 kinase beta-2 isoform X1 [KO:K04688] [EC:2.7.11.1]
129510988  RPS6KB1; ribosomal protein S6 kinase beta-1 isoform X1 [KO:K04688] [EC:2.7.11.1]
129493669  CHUK; inhibitor of nuclear factor kappa-B kinase subunit alpha isoform X1 [KO:K04467] [EC:2.7.11.10]
129515857  IKBKB; inhibitor of nuclear factor kappa-B kinase subunit beta isoform X1 [KO:K07209] [EC:2.7.11.10]
129517602  IKBKG; NF-kappa-B essential modulator isoform X1 [KO:K07210]
129499457  NFKBIA; NF-kappa-B inhibitor alpha [KO:K04734]
129499646  NFKBIB; NF-kappa-B inhibitor beta [KO:K02581]
129513074  NFKBIE; NF-kappa-B inhibitor epsilon [KO:K05872]
129521190  NFKB1; nuclear factor NF-kappa-B p105 subunit isoform X1 [KO:K02580]
129503049  RELA; transcription factor p65 isoform X1 [KO:K04735]
129512215  IFNG; interferon gamma [KO:K04687]
129509273  IFNGR1; interferon gamma receptor 1 [KO:K05132]
129502066  IFNGR2; interferon gamma receptor 2 isoform X1 [KO:K05133]
129497055  JAK1; tyrosine-protein kinase JAK1 [KO:K11217] [EC:2.7.10.2]
129499911  JAK2; tyrosine-protein kinase JAK2 [KO:K04447] [EC:2.7.10.2]
129522804  STAT1; signal transducer and activator of transcription 1-alpha/beta [KO:K11220]
129506479  STAT3; signal transducer and activator of transcription 3 isoform X1 [KO:K04692]
129516767  TLR2; toll-like receptor 2 [KO:K10159]
129494517  TLR4; toll-like receptor 4 isoform X1 [KO:K10160]
129522130  TLR9; toll-like receptor 9 [KO:K10161]
129496815  TIRAP; toll/interleukin-1 receptor domain-containing adapter protein [KO:K05403]
129506934  MYD88; myeloid differentiation primary response protein MyD88 [KO:K04729]
129494142  TRAF6; TNF receptor-associated factor 6 isoform X1 [KO:K03175] [EC:2.3.2.27]
129495445  NFATC1; nuclear factor of activated T-cells, cytoplasmic 1 isoform X1 [KO:K04446]
129514485  nuclear factor of activated T-cells, cytoplasmic 1-like isoform X1 [KO:K04446]
129496345  NFATC2; nuclear factor of activated T-cells, cytoplasmic 2 isoform X1 [KO:K17332]
129497947  NFATC3; nuclear factor of activated T-cells, cytoplasmic 3 isoform X1 [KO:K17333]
129522440  TICAM1; TIR domain-containing adapter molecule 1 [KO:K05842]
129499909  CD274; programmed cell death 1 ligand 1 isoform X1 [KO:K06745]
129523147  PDCD1; programmed cell death protein 1 [KO:K06744]
129503493  PTPN6; tyrosine-protein phosphatase non-receptor type 6 isoform X1 [KO:K05697] [EC:3.1.3.48]
129507762  PTPN11; tyrosine-protein phosphatase non-receptor type 11 [KO:K07293] [EC:3.1.3.48]
129497322  tyrosine-protein phosphatase non-receptor type 11-like [KO:K07293] [EC:3.1.3.48]
129503079  BATF2; basic leucine zipper transcriptional factor ATF-like 2 isoform X1 [KO:K09034]
129496248  BATF; basic leucine zipper transcriptional factor ATF-like isoform X1 [KO:K09034]
129505967  BATF3; basic leucine zipper transcriptional factor ATF-like 3 [KO:K09034]
129494272  CSNK2A1; casein kinase II subunit alpha [KO:K03097] [EC:2.7.11.1]
129509341  casein kinase II subunit alpha-like [KO:K03097] [EC:2.7.11.1]
129513503  CSNK2A2; casein kinase II subunit alpha' isoform X1 [KO:K03097] [EC:2.7.11.1]
129512954  CSNK2B; casein kinase II subunit beta [KO:K03115]
129503501  CD4; T-cell surface glycoprotein CD4 [KO:K06454]
129513760  LCK; tyrosine-protein kinase Lck [KO:K05856] [EC:2.7.10.2]
129497000  T-cell surface glycoprotein CD3 epsilon chain isoform X1 [KO:K06451]
129497001  T-cell surface glycoprotein CD3 gamma chain [KO:K06452]
129514977  uncharacterized protein LOC129514977 [KO:K10784]
129508837  CD247; T-cell surface glycoprotein CD3 zeta chain isoform X1 [KO:K06453]
129497002  T-cell surface glycoprotein CD3 delta chain [KO:K06450]
129511715  tyrosine-protein kinase ZAP-70 [KO:K07360] [EC:2.7.10.2]
129511556  MAP3K3; mitogen-activated protein kinase kinase kinase 3 isoform X1 [KO:K04421] [EC:2.7.11.25]
129497110  MAP2K3; dual specificity mitogen-activated protein kinase kinase 3 [KO:K04432] [EC:2.7.12.2]
129508745  MAP2K6; dual specificity mitogen-activated protein kinase kinase 6 isoform X1 [KO:K04433] [EC:2.7.12.2]
129511619  MAPK11; mitogen-activated protein kinase 11 isoform X1 [KO:K04441] [EC:2.7.11.24]
129511620  MAPK12; mitogen-activated protein kinase 12 isoform X1 [KO:K04441] [EC:2.7.11.24]
129512956  MAPK13; mitogen-activated protein kinase 13 isoform X1 [KO:K04441] [EC:2.7.11.24]
129512957  MAPK14; mitogen-activated protein kinase 14 isoform X1 [KO:K04441] [EC:2.7.11.24]
129519697  LAT; linker for activation of T-cells family member 1 isoform X1 [KO:K07362]
129493567  PLCG1; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 isoform X1 [KO:K01116] [EC:3.1.4.11]
129523448  PPP3CC; serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
129509604  PPP3CB; serine/threonine-protein phosphatase 2B catalytic subunit beta isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
129521210  PPP3CA; protein phosphatase 3 catalytic subunit alpha isoform X1 [KO:K04348] [EC:3.1.3.16]
129495049  PPP3R2; calcineurin subunit B type 2 [KO:K06268]
129511439  PPP3R1; calcineurin subunit B type 1 [KO:K06268]
129504178  RASGRP1; LOW QUALITY PROTEIN: RAS guanyl-releasing protein 1 [KO:K04350]
129522995  CD28; T-cell-specific surface glycoprotein CD28 [KO:K06470]
129513717  PRKCQ; protein kinase C theta type [KO:K18052] [EC:2.7.11.13]
Compound
C00076  Calcium cation
C00165  Diacylglycerol
C01245  D-myo-Inositol 1,4,5-trisphosphate
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ
  Title
PD-L1.
  Journal
J Clin Pathol 71:189-194 (2018)
DOI:10.1136/jclinpath-2017-204853
Reference
  Authors
Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X
  Title
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
  Journal
Urol Oncol 35:14-20 (2017)
DOI:10.1016/j.urolonc.2016.10.004
Reference
  Authors
Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J
  Title
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
  Journal
Front Pharmacol 9:536 (2018)
DOI:10.3389/fphar.2018.00536
Reference
  Authors
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z
  Title
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
  Journal
Mol Cancer 18:10 (2019)
DOI:10.1186/s12943-018-0928-4
Reference
  Authors
Bardhan K, Anagnostou T, Boussiotis VA
  Title
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
  Journal
Front Immunol 7:550 (2016)
DOI:10.3389/fimmu.2016.00550
Reference
  Authors
Shi Y
  Title
Regulatory mechanisms of PD-L1 expression in cancer cells.
  Journal
Cancer Immunol Immunother 67:1481-1489 (2018)
DOI:10.1007/s00262-018-2226-9
Reference
  Authors
Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T
  Title
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
  Journal
Oncogene 37:4639-4661 (2018)
DOI:10.1038/s41388-018-0303-3
Reference
  Authors
Chen J, Jiang CC, Jin L, Zhang XD
  Title
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
  Journal
Ann Oncol 27:409-16 (2016)
DOI:10.1093/annonc/mdv615
Reference
  Authors
Glodde N, Holzel M
  Title
RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
  Journal
Immunity 47:1007-1009 (2017)
DOI:10.1016/j.immuni.2017.12.001
Reference
  Authors
Ritprajak P, Azuma M
  Title
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
  Journal
Oral Oncol 51:221-8 (2015)
DOI:10.1016/j.oraloncology.2014.11.014
Reference
  Authors
Nirschl CJ, Drake CG
  Title
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
  Journal
Clin Cancer Res 19:4917-24 (2013)
DOI:10.1158/1078-0432.CCR-12-1972
Reference
  Authors
Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, Cheong HC, Yong YK, Larsson M, Shankar EM
  Title
T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses.
  Journal
Front Immunol 9:2569 (2018)
DOI:10.3389/fimmu.2018.02569
Reference
  Authors
Sharpe AH, Pauken KE
  Title
The diverse functions of the PD1 inhibitory pathway.
  Journal
Nat Rev Immunol 18:153-167 (2018)
DOI:10.1038/nri.2017.108
Reference
  Authors
Boussiotis VA
  Title
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
  Journal
N Engl J Med 375:1767-1778 (2016)
DOI:10.1056/NEJMra1514296
Reference
  Authors
Arasanz H, Gato-Canas M, Zuazo M, Ibanez-Vea M, Breckpot K, Kochan G, Escors D
  Title
PD1 signal transduction pathways in T cells.
  Journal
Oncotarget 8:51936-51945 (2017)
DOI:10.18632/oncotarget.17232
Reference
  Authors
Zuazo M, Gato-Canas M, Llorente N, Ibanez-Vea M, Arasanz H, Kochan G, Escors D
  Title
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
  Journal
Ann Transl Med 5:385 (2017)
DOI:10.21037/atm.2017.06.11
Reference
  Authors
Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA
  Title
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
  Journal
Mol Cell Biol 33:3091-8 (2013)
DOI:10.1128/MCB.00319-13
Reference
  Authors
Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X
  Title
New immunotherapies targeting the PD-1 pathway.
  Journal
Trends Pharmacol Sci 36:587-95 (2015)
DOI:10.1016/j.tips.2015.06.005
Reference
  Authors
Ok CY, Young KH
  Title
Targeting the programmed death-1 pathway in lymphoid neoplasms.
  Journal
Cancer Treat Rev 54:99-109 (2017)
DOI:10.1016/j.ctrv.2017.01.009
Related
pathway
npo04010  MAPK signaling pathway
npo04020  Calcium signaling pathway
npo04066  HIF-1 signaling pathway
npo04151  PI3K-Akt signaling pathway
npo04514  Cell adhesion molecules
npo04620  Toll-like receptor signaling pathway
npo04660  T cell receptor signaling pathway
KO pathway
ko05235   
LinkDB

DBGET integrated database retrieval system